The Effect of Tocilizumab on Inflammatory Markers in Patients Hospitalized with Serious Infections. Case Series and Review of Literature

The Effect of Tocilizumab on Inflammatory Markers in Patients Hospitalized with Serious Infections. Case Series and Review of Literature

Background: The human anti-IL-6 receptor antibody tocilizumab (TCZ) has been approved for the treatment of rheumatoid arthritis (RA) and giant cell arteritis (GCA). It is observed that CRP levels drop quickly after starting TCZ treatment. This may lead to misinterpretation of laboratory results when...

Full description

Bibliographic Details
Main Authors: Mark Berman, Ronen Ben-Ami, Shlomo Berliner, Marina Anouk, Ilana Kaufman, Adi Broyde, Sara Borok, Ori Elkayam
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Life
Subjects:
tocilizumab
infection
rheumatoid arthritis
giant cell arteritis
C-reactive protein
inflammation
Online Access:https://www.mdpi.com/2075-1729/11/3/258

Internet

https://www.mdpi.com/2075-1729/11/3/258

Similar Items